XOMA-213 is under clinical development by XOMA and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect XOMA-213’s likelihood of approval (LoA) and phase transition for Hyperprolactinaemia took place on 18 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their XOMA-213 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
XOMA-213 (LFA-102) is under development for the treatment of various hyperprolactinemias. The therapeutic candidate is administered through intravenous route. The therapeutic candidate is a anti-prolactin receptor humanized monoclonal antibody of the IgG1 kappa subtype. It was also under development for the treatment of prolactin receptor positive castration-resistant prostate cancer, metastatic breast cancer and uterine leiomyoma.
XOMA, formerly XOMA Ltd, is a biopharmaceutical company. It develops antibody-based therapeutics. Its lead product, Gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include RZ358, XMetA, X213 (formerly LFA 102) and PTH1R. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 is an allosteric inhibitor of prolactin action. XOMA has a developed proprietary antibody platform, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. XOMA is headquartered in Berkeley, California, the US.
Quick View XOMA-213 LOA Data
|Highest Development Stage|